Gilead Science Korea (CEO Seung-Woo Lee) celebrated the 3rd anniversary of the domestic launch of its HIV treatment ‘Bictarvi (bictegravir 50mg, emtricitabine 200mg, tenofovir alafenamide 25mg tablets)’ in Korea on the 16th of last month. It was announced on the 26th that (Sat) the company employees gathered and held a commemorative event.
Bictabi, a single-tablet combination HIV treatment, obtained approval from the Ministry of Food and Drug Safety in January 2019 and was released in July of the same year, marking the 3rd anniversary of its release this year. Accordingly, executives and staff, including CEO Lee Seung-woo of Gilead Science Korea, gathered to reflect on the hard work and achievements of the three years since its launch. In addition, we had time to ponder and discuss how we can contribute to the domestic HIV infection control situation, which is experiencing difficulties in diagnosis and treatment due to the aftermath of the COVID-19 pandemic.
The executives and staff who participated in the commemorative event also had time to comfort the suffering of HIV-infected people who suffered from discrimination and stigma. Individual executives and employees wore their t-shirts with messages of support they wanted to convey to people living with HIV, and pledged to improve social awareness for people living with HIV.
Gilead Science Korea is constantly striving to improve the misconception about HIV/AIDS in Korea and promote early detection and rapid treatment of HIV for HIV-infected people who are in the blind spot of treatment, such as facing social discrimination and experiencing difficulties in hospital visits. has been implementing
Among the social contribution activities that Gilead Sciences Korea has been carrying out for HIV-infected people so far include: ▲ Homosexual HIV/AIDS screening opportunities and prevention education support activities started in 2014 ▲ Homosexual HIV/AIDS screening project ▲ Difficulties of people living with HIV since 2015 An in-house campaign to sympathize with and revive the will to achieve a cure for HIV ▲Inspired by the 90-90-90 strategy of ‘UNAIDS’ since 2016 etc. In addition, it operated the ‘Welfare Support Program for the Poor People with HIV,’ and sponsored the ‘Korea AIDS Prevention Foundation’ welfare project to prevent the infected people from giving up on their lives for economic reasons, considering that 1 out of 6 infected people is a beneficiary. .
Seungwoo Lee, CEO of Gilead Sciences Korea, said, “It was meaningful to think about how the company could make efforts to solve the heavy task of resolving social discrimination and stigma against HIV-infected people at the time of the 3rd anniversary of the launch of Biktarvy in Korea.” According to the U=U (Undetectable=Untransmittable) concept, which has been established as a global trend, HIV-infected people have little contagiousness because the virus is not detected in the blood even if they take the drug continuously. Gilead Science Korea will do its best to help eliminate misconceptions and prejudices by delivering correct information about HIV disease, and to take one step closer to ending HIV/AIDS by developing and supplying innovative treatments.”